Form 4: Supernus Pharmaceuticals Executive Reports Stock Transactions

Frank Mottola, SVP at Supernus Pharmaceuticals, reports acquisition and disposal of common stock and derivative securities.

Summary

• Frank Mottola, a Senior Vice President at Supernus Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On February 21, 2025, Mottola acquired 1,125 shares of common stock from the settlement of Performance Share Units and disposed of 552 shares to cover tax withholding.
• On February 22, 2025, Mottola acquired 750 and 1,250 shares of common stock.
• On February 23, 2025, Mottola acquired 1,875 shares of common stock.
• Following these transactions, Mottola directly owns 12,899 shares of Supernus Pharmaceuticals common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing of stock transactions. The acquisitions through vesting are mildly positive, while the tax-related disposal is neutral.

Positives

• The acquisition of shares through vesting indicates confidence in the company's performance.

Negatives

• The disposal of shares to cover tax obligations could be interpreted as a slight negative, although it's a common practice.

Risks

• Executive stock transactions can sometimes be interpreted as a reflection of the executive's sentiment about the company's future prospects, although this is not necessarily the case here.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are regularly monitored by investors for insights into management's perspective on the company's value and future prospects.

Comparison to Industry Standards

• Form 4 filings are standard practice for executives in publicly traded companies like Supernus Pharmaceuticals, similar to filings made by executives at companies like Teva Pharmaceuticals and Mylan (now Viatris).
• The vesting schedules for restricted stock units (RSUs) and performance share units (PSUs) are typical compensation components used across the pharmaceutical industry to align executive incentives with company performance, comparable to equity compensation plans at companies such as Amgen and Biogen.

Stakeholder Impact

• The transactions may have a minor impact on shareholder sentiment, depending on how they interpret the executive's actions.

Key Dates

Keywords

Supernus Pharmaceuticals, Form 4, Stock Transactions, Beneficial Ownership, Frank Mottola, Performance Share Units, Restricted Stock Units